239 related articles for article (PubMed ID: 36143203)
1. DNA Directed Pro-Dopamine Regulation Coupling Subluxation Repair, H-Wave
Bajaj A; Blum K; Bowirrat A; Gupta A; Baron D; Fugel D; Nicholson A; Fitch T; Downs BW; Bagchi D; Dennen CA; Badgaiyan RD
J Pers Med; 2022 Aug; 12(9):. PubMed ID: 36143203
[TBL] [Abstract][Full Text] [Related]
2. Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors.
Gupta A; Bowirrat A; Gomez LL; Baron D; Elman I; Giordano J; Jalali R; Badgaiyan RD; Modestino EJ; Gold MS; Braverman ER; Bajaj A; Blum K
Int J Environ Res Public Health; 2022 Jan; 19(1):. PubMed ID: 35010811
[TBL] [Abstract][Full Text] [Related]
3. Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?
Blum K; Dennen CA; Elman I; Bowirrat A; Thanos PK; Badgaiyan RD; Downs BW; Bagchi D; Baron D; Braverman ER; Gupta A; Green R; McLaughlin T; Barh D; Gold MS
J Pers Med; 2022 Oct; 12(10):. PubMed ID: 36294858
[TBL] [Abstract][Full Text] [Related]
4. Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS).
Blum K; Baron D; McLaughlin T; Gold MS
J Neurol Sci; 2020 Apr; 411():116733. PubMed ID: 32088516
[TBL] [Abstract][Full Text] [Related]
5. Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)?
Blum K; Gold M; Modestino EJ; Baron D; Boyett B; Siwicki D; Lott L; Podesta A; Roy AK; Hauser M; Downs BW; Badgaiyan RD
J Syst Integr Neurosci; 2018 May; 4():. PubMed ID: 31750006
[TBL] [Abstract][Full Text] [Related]
6. A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration.
Blum K; Kazmi S; Modestino EJ; Downs BW; Bagchi D; Baron D; McLaughlin T; Green R; Jalali R; Thanos PK; Elman I; Badgaiyan RD; Bowirrat A; Gold MS
J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33809702
[TBL] [Abstract][Full Text] [Related]
7. Beyond Mor: Can Induction of Dopamine Homeostasis Along with Electrotherapy Attenuate the Opioid Crisis?
Blum K; Bowirrat A; Braverman ER; Dennen C; Zeine F; Jafari N; Sunder K; Thanos PK; Baron D; Barh D; Gupta A; Bagchi D; Gold MS; Badgaiyan RD
Clin Exp Psychol; 2023 Mar; 9(2):1-3. PubMed ID: 37363693
[TBL] [Abstract][Full Text] [Related]
8. Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence?
Madigan MA; Gupta A; Bowirrat A; Baron D; Badgaiyan RD; Elman I; Dennen CA; Braverman ER; Gold MS; Blum K
Int J Environ Res Public Health; 2022 May; 19(11):. PubMed ID: 35681980
[TBL] [Abstract][Full Text] [Related]
9. Putative COVID- 19 Induction of Reward Deficiency Syndrome (RDS) and Associated Behavioral Addictions with Potential Concomitant Dopamine Depletion: Is COVID-19 Social Distancing a Double Edged Sword?
Blum K; Cadet JL; Baron D; Badgaiyan RD; Brewer R; Modestino EJ; Gold MS
Subst Use Misuse; 2020; 55(14):2438-2442. PubMed ID: 32957797
[TBL] [Abstract][Full Text] [Related]
10. Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia's Effect on Addictive and Non-Addictive Behaviors in a Nuclear Family.
Dennen CA; Blum K; Bowirrat A; Thanos PK; Elman I; Ceccanti M; Badgaiyan RD; McLaughlin T; Gupta A; Bajaj A; Baron D; Downs BW; Bagchi D; Gold MS
J Pers Med; 2022 Nov; 12(11):. PubMed ID: 36579592
[TBL] [Abstract][Full Text] [Related]
11. A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management".
Blum K; Steinberg B; Gondre-Lewis MC; Baron D; Modestino EJ; Badgaiyan RD; Downs BW; Bagchi D; Brewer R; McLaughlin T; Bowirrat A; Gold M
Psychol Res Behav Manag; 2021; 14():2115-2134. PubMed ID: 34949945
[TBL] [Abstract][Full Text] [Related]
12. Should We Embrace the Incorporation of Genetically Guided "Dopamine Homeostasis" in the Treatment of Reward Deficiency Syndrome (RSD) as a Frontline Therapeutic Modality?
Blum K; Raza A; Schultz T; Jalali R; Green R; Brewer R; Thanos PK; McLaughlin T; Baron D; Bowirrat A; Elman I; Downs BW; Bagchi D; Badgaiyan RD
Acta Sci Neurol; 2021 Feb; 4(2):17-24. PubMed ID: 33681869
[TBL] [Abstract][Full Text] [Related]
13. Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
Blum K; Febo M; Fried L; Li M; Dushaj K; Braverman ER; McLaughlin T; Steinberg B; Badgaiyan RD
Subst Use Misuse; 2017 Mar; 52(4):535-547. PubMed ID: 28033474
[TBL] [Abstract][Full Text] [Related]
14. Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated).
Kenneth B; Edward MJ; Marjorie GLC; David B; Bruce S; Panayotis TK; William DB; Davis S; Lisa L; Eric BR; Mark M; David M; Lyle F; Rajendra BD
CPQ Neurol Psychol; 2018; 1(2):. PubMed ID: 30957097
[TBL] [Abstract][Full Text] [Related]
15. Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).
Blum K; Bowirrat A; Baron D; Lott L; Ponce JV; Brewer R; Siwicki D; Boyett B; Gondre-Lewis MC; Smith DE; Panayotis K T; Badgaiyan S; Hauser M; Fried L; A R; Downs BW; Badgaiyan RD
J Syst Integr Neurosci; 2020 Aug; 6(2):. PubMed ID: 33614164
[TBL] [Abstract][Full Text] [Related]
16. Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis.
Blum K; Modestino EJ; Neary J; Gondré-Lewis MC; Siwicki D; Moran M; Hauser M; Braverman ER; Baron D; Steinberg B; Laughlin TM; Badgaiyan RD
Biomed J Sci Tech Res; 2018 Jan; 2(2):1-4. PubMed ID: 30370423
[TBL] [Abstract][Full Text] [Related]
17. The Future is Now for Precision Genomic Addiction Medicine as a Frontline Modality for Inducing "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
Gilley ED; Bowirrat A; Gupta A; Giordano J; A Dennen C; R Braverman E; D Badgaiyan R; McLaughlin T; Baron D; Blum K
Curr Pharm Biotechnol; 2023 Apr; ():. PubMed ID: 37102488
[TBL] [Abstract][Full Text] [Related]
18. Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) During Adolescent Brain Development.
Blum K; Bowirrat A; Gondre Lewis MC; Simpatico TA; Ceccanti M; Steinberg B; Modestino EJ; Thanos PK; Baron D; McLaughlin T; Brewer R; Badgaiyan RD; Ponce JV; Lott L; Gold MS
Curr Psychopharmacol; 2021 Feb; 10():. PubMed ID: 34707969
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic dysfunction: Role for genetic & epigenetic testing in the new psychiatry.
Blum K; Ashford JW; Kateb B; Sipple D; Braverman E; Dennen CA; Baron D; Badgaiyan R; Elman I; Cadet JL; Thanos PK; Hanna C; Bowirrat A; Modestino EJ; Yamamoto V; Gupta A; McLaughlin T; Makale M; Gold MS
J Neurol Sci; 2023 Oct; 453():120809. PubMed ID: 37774561
[TBL] [Abstract][Full Text] [Related]
20. Transmodulation of Dopaminergic Signaling to Mitigate Hypodopminergia and Pharmaceutical Opioid-Induced Hyperalgesia.
Brewer R; Blum K; Bowirrat A; Modestino EJ; Baron D; Badgaiyan RD; Moran M; Boyett B; Gold MS
Curr Psychopharmacol; 2020; 9(3):164-184. PubMed ID: 37361136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
